Inactive Instrument

Elefirst Science and Technology Co., Ltd. Stock

Equities

300356

CNE100001M53

Electrical Components & Equipment

Dynamic Chart
Jiang Qingping acquired 5% stake in Nanjing Zhiyou Shangyun Technology Co., Ltd. CI
Elefirst Science and Technology Co., Ltd.(SZSE:300356) dropped from Shenzhen Stock Exchange A Share Index CI
Elefirst Science and Technology Co., Ltd.(SZSE:300356) dropped from Shenzhen Stock Exchange Composite Index CI
Elefirst Science and Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Elefirst Science and Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Elefirst Science and Technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Elefirst Science and Technology Co., Ltd. Announces Board Appointments CI
Jiang Qingping agreed to acquire 5% stake in Nanjing Zhiyou Shangyun Technology Co., Ltd. CI
Elefirst Science and Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Elefirst Science and Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
EleFirst Science & Technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Elefirst Science & Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021 CI
EleFirst Science & Technology : Shenzhen Bourse Assigns Risk Alert Status to Elefirst's Shares MT
EleFirst Science & Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
Elefirst Science & Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020 CI
More news
Managers TitleAgeSince
Chief Executive Officer 55 99-12-31
Director/Board Member 53 99-12-31
Members of the board TitleAgeSince
Director/Board Member 64 -
Director/Board Member 56 -
Chairman 58 96-12-31
More insiders
SHENZHEN CAU TECHNOLOGY CO., LTD is a China-based company principally engaged in the biomedical business. The Company is principally involved in the research, development, manufacture and sale of pharmaceutical products. The Company's main products include compound dichloroacetic acid diisopropylamine for injection, amifostine for injection, clindamycin phosphate for injection and urokinase for injection. The Company distributes its products in domestic market.
More about the company
  1. Stock Market
  2. Equities
  3. 300356 Stock